Teleflex (NYSE:TFX) Lowered to Market Perform Rating by Raymond James

Raymond James lowered shares of Teleflex (NYSE:TFX) from an outperform rating to a market perform rating in a research report released on Friday, Marketbeat.com reports.

Several other research analysts have also issued reports on TFX. StockNews.com upgraded Teleflex from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a report on Monday, December 16th. Royal Bank of Canada dropped their price target on Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Truist Financial decreased their target price on Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Finally, Citizens Jmp cut Teleflex from an “outperform” rating to a “market perform” rating in a research report on Thursday. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Teleflex currently has an average rating of “Hold” and an average price target of $196.83.

Teleflex Price Performance

Shares of TFX stock opened at $132.58 on Friday. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. The company has a market cap of $6.16 billion, a P/E ratio of 26.36, a P/E/G ratio of 1.73 and a beta of 1.16. Teleflex has a twelve month low of $130.60 and a twelve month high of $249.90. The business has a fifty day simple moving average of $175.44 and a 200 day simple moving average of $205.04.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, beating the consensus estimate of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The firm had revenue of $795.40 million during the quarter, compared to the consensus estimate of $813.24 million. On average, sell-side analysts forecast that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Friday, March 7th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.03%. The ex-dividend date is Friday, March 7th. Teleflex’s dividend payout ratio (DPR) is currently 27.04%.

Institutional Investors Weigh In On Teleflex

Several hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC bought a new stake in shares of Teleflex in the 4th quarter valued at about $29,000. Avior Wealth Management LLC lifted its stake in shares of Teleflex by 190.6% in the 3rd quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company’s stock valued at $38,000 after acquiring an additional 101 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Teleflex in the 3rd quarter valued at about $40,000. True Wealth Design LLC lifted its stake in shares of Teleflex by 16,600.0% in the 3rd quarter. True Wealth Design LLC now owns 167 shares of the medical technology company’s stock valued at $41,000 after acquiring an additional 166 shares during the last quarter. Finally, Capital Performance Advisors LLP bought a new stake in shares of Teleflex in the 3rd quarter valued at about $54,000. Institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.